Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Gross Margin (2019 - 2023)

Benitec Biopharma (BNTC) has disclosed Gross Margin for 5 consecutive years, with 100.0% as the latest value for Q2 2023.

  • Quarterly Gross Margin changed N/A to 100.0% in Q2 2023 from the year-ago period, while the trailing twelve-month figure was 1471.43% through Mar 2024, down 155819.0% year-over-year, with the annual reading at 100.0% for FY2023, 1233.0% up from the prior year.
  • Gross Margin hit 100.0% in Q2 2023 for Benitec Biopharma, roughly flat from 100.0% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 100.0% in Q4 2021 to a low of 1800.0% in Q4 2020.
  • Historically, Gross Margin has averaged 182.68% across 5 years, with a median of 21.21% in 2019.
  • Biggest five-year swings in Gross Margin: crashed -150260bps in 2020 and later soared 190000bps in 2021.
  • Year by year, Gross Margin stood at 297.4% in 2019, then plummeted by -505bps to 1800.0% in 2020, then skyrocketed by 106bps to 100.0% in 2021, then changed by 0bps to 100.0% in 2022, then changed by 0bps to 100.0% in 2023.
  • Business Quant data shows Gross Margin for BNTC at 100.0% in Q2 2023, 100.0% in Q1 2023, and 100.0% in Q4 2022.